15.02.2013 Views

world cancer report - iarc

world cancer report - iarc

world cancer report - iarc

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Fig. 5.124 Pancreatic duct showing high-grade<br />

intraepithelial neoplasia.<br />

Fig. 5.125 Well-differentiated, mucus-secreting<br />

invasive ductal adenocarcinoma of the pancreas.<br />

Hereditary conditions<br />

Around 10% of cases of pancreatic <strong>cancer</strong><br />

exhibit some degree of familial risk, this<br />

fraction being the highest for any human<br />

organ site [6]. In this context, germline<br />

mutations have been identified in a number<br />

of oncogenes and tumour suppressors,<br />

including BRCA2, (predisposing to<br />

breast and pancreatic carcinoma) and<br />

p16 INK4 (predisposing to melanoma and<br />

pancreatic <strong>cancer</strong>) (Table 5.13). The<br />

STK11/LKB1 gene is mutated in Peutz-<br />

Jeghers syndrome patients, this group<br />

being predisposed to pancreatic <strong>cancer</strong><br />

[7]. Sufferers from hereditary pancreatitis<br />

experience attacks of acute pancreatitis<br />

from an early age and face a 40% risk of<br />

<strong>cancer</strong> by age 70. Most families appear to<br />

possess one of two mutations in the<br />

cationic trypsinogen gene (chromosome<br />

7q35) [8] which cause the production of a<br />

mutant protein. Consequently, associated<br />

enzymatic activity is not inactivated and is<br />

hypothesized to contribute to autodigestion<br />

of the pancreas and pancreatitis; <strong>cancer</strong><br />

may then be a consequence of the<br />

prolonged inflammatory microenvironment<br />

in the pancreas. Other conditions<br />

250 Human <strong>cancer</strong>s by organ site<br />

Gene Chromosome Mechanism of alteration % of <strong>cancer</strong>s<br />

Oncogenes<br />

KRAS 12p Point mutation > 90<br />

MYB, AKT2, AIB1 6q, 19q, 20q Amplification 1 10-20<br />

ERBB2 (HER/2-neu) 17q Overexpression 70<br />

Tumour suppressor genes<br />

p16 INK4A 9p Homozygous deletion 40<br />

Loss of heterozygosity 40<br />

and intragenic mutation<br />

Promoter hypermethylation 15<br />

p53 17p Loss of heterozygosity 50-70<br />

and intragenic mutation<br />

DPC4 18q Homozygous deletion 35<br />

Loss of heterozygosity 20<br />

and intragenic mutation<br />

BRCA2 13q Inherited intragenic 7<br />

mutation and loss<br />

of heterozygosity<br />

MKK4 17p Homozygous deletion, 4<br />

loss of heterozygosity<br />

and intragenic mutation<br />

LKB1/STK11 19p Loss of heterozygosity 5<br />

and intragenic mutation,<br />

homozygous deletion<br />

ALK5 and TGF βR2 9q, 3p Homozygous deletion 4<br />

DNA mismatch repair<br />

MSH2, MLH1, others 2p, 3p, others Unknown

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!